Janux therapeutics appoints janeen doyle as chief corporate and business development officer

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced the appointment of janeen doyle, mba, as chief corporate and business development officer. “janeen's unique blend of corporate development, strategic execution, and cli.
JANX Ratings Summary
JANX Quant Ranking